| アブストラクト | AIM: The present study aimed to estimate the anaphylaxis rates following mRNA COVID-19 vaccination in children and adolescents in Europe. METHODS: We retrieved data on 371 anaphylaxis cases following mRNA COVID-19 vaccination in children </= 17 years old notified to EudraVigilance as of October 8, 2022. Overall, 27,120,512 doses of BNT162b2 vaccine and 1,400,300 doses of mRNA-1273 vaccine have been delivered to children during the study period. RESULTS: The overall mean anaphylaxis rate was 12.81 [95% confidence interval (CI): 11.49-14.12] per 10(6) mRNA vaccine doses [12.14 (95% CI: 6.37-17.91) per 10(6) doses for mRNA-1273 and 12.84 (95% CI: 11.49-14.19) per 10(6) doses for BNT162b2]. Children 12-17 years old accounted for 317 anaphylaxis cases, followed by 48 cases in children 3-11 years old, and 6 cases in children 0-2 years old. Children 10-17 years old had a mean anaphylaxis rate of 13.52 (95% CI: 12.03-15.00) cases per 10(6) mRNA vaccine doses and children 5-9 years old had a mean anaphylaxis rate of 9.51 (95% CI: 6.82-12.20) cases per 10(6) mRNA vaccine doses. There were two fatalities, both in the 12-17 years age group. The fatal anaphylaxis rate was 0.07 cases per 10(6) mRNA vaccine doses. CONCLUSIONS: Anaphylaxis is a rare adverse event after receiving an mRNA COVID-19 vaccine in children. Continuous surveillance of serious adverse events is needed to guide vaccination policies as we move towards SARS-CoV-2 endemicity. Larger real-world studies on COVID-19 vaccination in children, using clinical case confirmation, are imperative. |
|---|
| 組織名 | Directorate of Research, Studies and Documentation, National Public Health;Organization, Athens, Greece. Electronic address: maltezou.helena@gmail.com.;Laboratory of Pharmaceutical Technology, Department of Pharmacy, School of Health;Sciences, University of Patras, Patras, Greece.;Department of Microbiology, Medical School, National and Kapodistrian University;of Athens, Athens, Greece; Department of Microbiology, Andreas Syggros Hospital;for Skin and Venereal Diseases, National and Kapodistrian University of Athens,;161 21 Athens, Greece.;Department of Pharmacy, School of Health Sciences, University of Patras, Patras,;Greece.;of Athens, Athens, Greece. |
|---|
